derisking rare disease drug development and measuring impact and outcomes with andrew lo
Published 7 months ago • 99 plays • Length 45:31Download video MP4
Download video MP3
Similar videos
-
53:31
ai-powered real-world simulations for faster and value-based rare disease drug development
-
1:36:06
webinar: rdca-dap and eatris present rare disease drug development
-
48:02
rdca-dap - value of integrated data and analytics in rare disease drug development
-
29:30
accelerating drug development for rare diseases through data sharing and analysis
-
1:24:07
regulatory pathway and applications in drug development for rare diseases
-
3:33
4 signs of addictive behavior from our expert
-
5:27
what is the critical path method (cpm)?
-
5:51
3 texts that make him chase you (matthew hussey, get the guy)
-
8:03
rdca-dap: how the data and analytics platform accelerates rare disease drug development
-
57:08
industry perspective on drug development in rare diseases
-
46:37
clinical trial simulation tools advancing treatments in rare disease
-
11:08
rare disease endpoint advancement rdea pilot program
-
3:00:25
c-path rare & orphan disease conference am sessions sept 11, 2023
-
2:27
jane larkindale - why are c-path drug development tools important in rare disease drug development?
-
2:18:02
c-path rare & orphan disease conference day two pm sessions sept 12, 2023
-
53:31
a continuity of drug development for diseases across the lifespan
-
51:54
impact of rare disease initiatives at ema and health canada
-
51:31
fireside chat on impact on rare diseases at fda
-
1:34:43
eatx rdca-dap - webinar on ‘data sharing and analysis to support rare disease drug development‘
-
30:31
drug development and regulation in the age of precision medicine
-
1:03:05
innovative trial design approaches: model informed drug development in rare & neurological diseases